Table 3.
Outcome of non-neoadjuvant and neoadjuvant group
| Results | Non-neoadjuvant group | Neoadjuvant group | p value | ||
|---|---|---|---|---|---|
| (n = 25) | (n = 11) | ||||
| % | (n) | % | (n) | ||
| Surgical resection | 88% | (22/25) | 73% | (8/11) | 0.26 |
| Surgical approach | 0.55 | ||||
| Transanal | 29% | (6/21) | 13% | (1/8) | |
| Laparoscopic | 5% | (1/21) | 13% | (1/8) | |
| Open | 67% | (14/21) | 75% | (6/8) | |
| Extend of surgery | |||||
| Sphincter sparing | 76% | (16/21) | 75% | (6/8) | 0.94 |
| Stoma creation | 40% | (10/25) | 45% | (5/11) | 0.76 |
| Extend of resection | 0.47 | ||||
| R0 | 56% | (10/18) | 71.4% | (5/7) | |
| R1 | 44% | (8/18) | 29% | (2/7) | |
| Surgical complications | 16% | (4/25) | 9% | (1/11) | 0.58 |
| Ruptured tumour | 50% | (2/4) | 0% | (0/1) | |
| Perforated tumour | 50% | (2/4) | 0% | (0/1) | |
| Fistula | 0% | (0/4) | 100% | (1/1) | |
| Adjuvant therapy | 40% | (10/25) | 60% | (6/10) | 0.28 |
| Dose of adjuvant imatinib | 0.23 | ||||
| 400 mg | 100% | (8/8) | 83% | (5/6) | |
| 300 mg | 0% | (0/8) | 17% | (1/6) | |
| Duration of imatinib | 3.0 | (0.3 to 6.2) | 2.1 | (0.3 to 2.5) | 0.41 |
| (Median year) | |||||
| Total duration of imatinib | 3.1 | (0.3 to 6.2) | 2.0 | (0.3 to 3.1) | 0.40 |
| (Median year) | |||||
| Response to imatinib | 0.22 | ||||
| Complete response | 30% | (3/10) | 83% | (5/6) | |
| Partial response | 10% | (1/10) | 0% | (0/6) | |
| No response | 10% | (1/10) | 0% | (0/6) | |
| Progressive disease | 50% | (5/10) | 17% | (1/6) | |